$ELVN News

HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $64

Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $80

Jones Trading Maintains Buy on Enliven Therapeutics, Raises Price Target to $70

Enliven Therapeutics: Continuing The Pop Off; What Could Go Wrong?

Enliven Therapeutics, Inc. (ELVN) Presents at European Hematology Association (EHA) 2026 Congress - Slideshow

Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia - Slideshow

Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript

Enliven Therapeutics Presents Data From The Phase 1 Enable Clinical Trial Evaluating ELVN-001 In Patients With Previously Treated Chronic Myeloid Leukemia; Notes Encouraging Efficacy Data By 24 Weeks

Stifel Initiates Coverage On Enliven Therapeutics with Buy Rating, Announces Price Target of $60

A Look At Enliven Therapeutics (ELVN) Valuation As ENABLE Trial Data Update Nears

Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress

Enliven Therapeutics To Present Updated Phase 1 ELVN-001 Data In Chronic Myeloid Leukemia At EHA 2026 And Host Investor Webcast On June 11 At 8:30 a.m. ET

Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.

This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter

Enliven Therapeutics to Present at Upcoming Investor Conferences

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

Enliven Therapeutics To Present Phase 1 CML Data For ELVN-001, Showing Durable Molecular Response Rates And Favorable Safety In Heavily Pretreated Patients At EHA 2026

Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $59

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Assessing Enliven Therapeutics (ELVN) Valuation After Strong Recent Share Price Momentum